Bladder Cancer

For the first time, a drug combination (Padcev plus Keytruda) outperformed frontline chemotherapy for patients with locally advanced or metastatic urothelial carcinoma.

Adding Opdivo to a standard-of-care chemotherapy regimen in patients with unresectable or metastatic urothelial carcinoma improved progression-free and overall survival.

A recent phase 3 trial revealed that the primary endpoint was met with Keytruda for patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma.

Padcev plus Keytruda may improve survival outcomes for some patients with advanced urothelial cancer, according to preliminary data.

Balversa has been submitted to the FDA for approval to treat patients with locally advanced or metastatic urothelial carcinoma.

“I treat all of my patients like my friends and family,” said Dr. Ravi Munver of Hackensack University Medical Center, who first met Peter Kahan as his honors physics teacher more than 35 years ago.

Patients with nonmetastatic node-positive bladder cancer may have similar survival rates whether they underwent treatment with surgery or radical dose radiotherapy.

Prehabilitation can help patients become eligible for certain cancer treatments, or also help them recover from therapies, while also improving their overall health and fitness, an expert explained.

From Eric Braeden announces that he is cancer free to Tom Jones dying from cancer, this is what’s happening in the oncology space this week.

Findings from the phase 3 ATLAS and ENVISION trials reveal a non-surgical way to possibly benefit patients with low-grade, intermediate- risk non-muscle invasive bladder cancer.

A phase 1 trial just launched, and will evaluate IO102-IO103 plus Keytruda in patients with bladder cancer whose disease is unresponsive to BCG therapy.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.

A randomized clinical trial, CHEERS, determined that the combination of stereotactic body radiotherapy (SBRT) and immune checkpoint inhibitors (ICIs) were ineffective as treatment for patients with advanced solid tumors.

Immunotherapy with Opdivo plus cisplatin-based chemotherapy improved overall survival and progression-free survival in patients with unresectable or metastatic urothelial carcinoma.

A chemotherapy shortage is resulting in altered treatment plans for many patients with cancer. CURE® spoke with experts about what that means for patients — and what they can do about it.

Opting for telehealth appointments can make a big financial difference for rural-residing patients receiving urologic cancer care.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Findings from a recent study demonstrated that exposure to Agent Orange increased the risk for bladder cancer but did not affect the disease’s aggressiveness.

Here’s an overview of the new cancer regimens that gained Food and Drug Administration (FDA) approval in the spring of this year.

Acupuncture reduced pain “in a very significant way” and urinary symptoms for patients with non-muscle invasive bladder cancer who were undergoing BCG therapy.

The recent FDA approval of Padcev plus Keytruda for locally advanced/metastatic, chemotherapy-ineligible bladder cancer offers an “exciting opportunity” for this difficult-to-treat patient population, an expert said.

I developed tuberculosis — a rare but dangerous effect of certain bladder cancer treatments.

The FDA approved the combination for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for treatment with cisplatin-based chemotherapy.

The phase 2 DESTINY-PanTumor02 trial included patients with HER2-expressing solid tumors such as bladder, pancreatic and rare tumors.

Bladder cancer survivors face a bevy of challenges post-treatment, but an immediately available service strives to ease the burden.